drugset
drugset / Trial / NCT07138352

Bioavailability Study of XS003 (Nilotinib)

NCT07138352 ↗

Phase 1 Completed 48 enrolled Xspray Pharma AB
RandomizedCrossoverOpen-labelTreatment

Summary

An open label, single-center, randomized, two-treatment, two-period, two-sequence, single dose, crossover, study under fasted and fed conditions.

Timeline

Start
2024-10-03
Primary completion
2025-01-08
Completion
2025-01-08

Drugs

EvaluationDrugModalityDoseRoute
Subject XS003 Unknown 192 mg Oral

Indications

cancer